Oncotelic Therapeutics, Inc. (OTLC)
USD 0.05
(-25.71%)
USD 0.05
(-25.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.9 Million USD | -144.35% |
| 2022 | 17.81 Million USD | 256.4% |
| 2021 | -11.39 Million USD | 0.93% |
| 2020 | -11.5 Million USD | -55.68% |
| 2019 | -7.38 Million USD | -169.92% |
| 2018 | -2.73 Million USD | 80.18% |
| 2017 | -13.81 Million USD | -1.16% |
| 2016 | -13.65 Million USD | 0.0% |
| 2015 | -13.65 Million USD | -7.96% |
| 2014 | -12.64 Million USD | -52.8% |
| 2013 | -8.27 Million USD | -2.45% |
| 2012 | -8.07 Million USD | 16.31% |
| 2011 | -9.65 Million USD | 59.39% |
| 2010 | -23.77 Million USD | 3.87% |
| 2009 | -24.72 Million USD | -15.55% |
| 2008 | -21.4 Million USD | -4.96% |
| 2007 | -20.38 Million USD | -31.91% |
| 2006 | -15.45 Million USD | -29.79% |
| 2005 | -11.9 Million USD | -18.8% |
| 2004 | -10.02 Million USD | -19.79% |
| 2003 | -8.36 Million USD | 24.02% |
| 2002 | -11.01 Million USD | -166.11% |
| 2001 | -4.13 Million USD | 54.46% |
| 2000 | -9.08 Million USD | 13.03% |
| 1999 | -10.44 Million USD | 9.14% |
| 1998 | -11.5 Million USD | -41.98% |
| 1997 | -8.1 Million USD | -35.0% |
| 1996 | -6 Million USD | -62.16% |
| 1995 | -3.7 Million USD | -32.14% |
| 1994 | -2.8 Million USD | -40.0% |
| 1993 | -2 Million USD | -25.0% |
| 1992 | -1.6 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -408.67 Thousand USD | 44.47% |
| 2024 Q2 | -209.83 Thousand USD | 48.65% |
| 2023 Q4 | -735.98 Thousand USD | -738.27% |
| 2023 FY | -7.9 Million USD | -144.35% |
| 2023 Q3 | 115.3 Thousand USD | 101.71% |
| 2023 Q2 | -6.75 Million USD | -435.58% |
| 2023 Q1 | -1.26 Million USD | 75.44% |
| 2022 Q3 | -1.04 Million USD | -103.35% |
| 2022 Q4 | -5.13 Million USD | -392.95% |
| 2022 Q1 | -5.59 Million USD | -211.9% |
| 2022 Q2 | 31.14 Million USD | 656.56% |
| 2022 FY | 17.81 Million USD | 256.4% |
| 2021 Q4 | -1.79 Million USD | -14.82% |
| 2021 Q2 | -3.23 Million USD | -15.28% |
| 2021 FY | -11.39 Million USD | 0.93% |
| 2021 Q3 | -1.56 Million USD | 51.64% |
| 2021 Q1 | -2.8 Million USD | 18.52% |
| 2020 Q3 | -1.98 Million USD | -441.28% |
| 2020 FY | -11.5 Million USD | -55.68% |
| 2020 Q1 | -4.65 Million USD | -33.78% |
| 2020 Q2 | 582.09 Thousand USD | 112.5% |
| 2020 Q4 | -3.44 Million USD | -73.18% |
| 2019 Q2 | -1.18 Million USD | -87.85% |
| 2019 Q1 | -633 Thousand USD | -1.12% |
| 2019 FY | -7.38 Million USD | -169.92% |
| 2019 Q4 | -3.48 Million USD | -251.29% |
| 2019 Q3 | -991.12 Thousand USD | 16.65% |
| 2018 Q4 | -626 Thousand USD | 7.26% |
| 2018 Q2 | -642 Thousand USD | 19.14% |
| 2018 FY | -2.73 Million USD | 80.18% |
| 2018 Q1 | -794 Thousand USD | 67.38% |
| 2018 Q3 | -675 Thousand USD | -5.14% |
| 2017 Q1 | -3.95 Million USD | -14.62% |
| 2017 FY | -13.81 Million USD | -1.16% |
| 2017 Q4 | -2.43 Million USD | 31.17% |
| 2017 Q3 | -3.53 Million USD | 8.96% |
| 2017 Q2 | -3.88 Million USD | 1.87% |
| 2016 Q3 | -3.23 Million USD | 11.12% |
| 2016 Q4 | -3.45 Million USD | -6.71% |
| 2016 FY | -13.65 Million USD | 0.0% |
| 2016 Q1 | -3.32 Million USD | 16.16% |
| 2016 Q2 | -3.64 Million USD | -9.5% |
| 2015 Q1 | -2.77 Million USD | -5.08% |
| 2015 Q4 | -3.96 Million USD | -10.41% |
| 2015 FY | -13.65 Million USD | -7.96% |
| 2015 Q2 | -3.32 Million USD | -19.91% |
| 2015 Q3 | -3.59 Million USD | -8.06% |
| 2014 Q3 | -3.45 Million USD | 12.19% |
| 2014 Q1 | -2.63 Million USD | -25.42% |
| 2014 FY | -12.64 Million USD | -52.8% |
| 2014 Q2 | -3.92 Million USD | -49.39% |
| 2014 Q4 | -2.63 Million USD | 23.54% |
| 2013 Q3 | -2.64 Million USD | -59.98% |
| 2013 Q1 | -1.88 Million USD | -12.24% |
| 2013 Q4 | -2.09 Million USD | 20.75% |
| 2013 Q2 | -1.65 Million USD | 12.02% |
| 2013 FY | -8.27 Million USD | -2.45% |
| 2012 FY | -8.07 Million USD | 16.31% |
| 2012 Q1 | -1.89 Million USD | 19.36% |
| 2012 Q2 | -2.26 Million USD | -19.83% |
| 2012 Q3 | -2.24 Million USD | 0.84% |
| 2012 Q4 | -1.67 Million USD | 25.46% |
| 2011 Q1 | -863 Thousand USD | 50.49% |
| 2011 FY | -9.65 Million USD | 59.39% |
| 2011 Q4 | -2.34 Million USD | 33.25% |
| 2011 Q3 | -3.51 Million USD | -19.82% |
| 2011 Q2 | -2.93 Million USD | -239.75% |
| 2010 FY | -23.77 Million USD | 3.87% |
| 2010 Q2 | 2.53 Million USD | 123.01% |
| 2010 Q1 | -11.02 Million USD | -48.43% |
| 2010 Q3 | -13.53 Million USD | -633.54% |
| 2010 Q4 | -1.74 Million USD | 87.12% |
| 2009 Q3 | -6.47 Million USD | -22.8% |
| 2009 Q2 | -5.27 Million USD | 5.03% |
| 2009 FY | -24.72 Million USD | -15.55% |
| 2009 Q1 | -5.55 Million USD | -208.44% |
| 2009 Q4 | -7.43 Million USD | -14.75% |
| 2008 Q3 | -7.1 Million USD | -0.85% |
| 2008 Q1 | -5.44 Million USD | 6.07% |
| 2008 FY | -21.4 Million USD | -4.96% |
| 2008 Q4 | -1.8 Million USD | 74.68% |
| 2008 Q2 | -7.04 Million USD | -29.44% |
| 2007 Q4 | -5.79 Million USD | -9.9% |
| 2007 Q3 | -5.27 Million USD | 1.75% |
| 2007 FY | -20.38 Million USD | -31.91% |
| 2007 Q1 | -3.94 Million USD | -16.29% |
| 2007 Q2 | -5.36 Million USD | -35.99% |
| 2006 FY | -15.45 Million USD | -29.79% |
| 2006 Q4 | -3.39 Million USD | 8.98% |
| 2006 Q3 | -3.73 Million USD | 25.33% |
| 2006 Q2 | -4.99 Million USD | -49.73% |
| 2006 Q1 | -3.33 Million USD | 1.27% |
| 2005 Q1 | -2.02 Million USD | 9.83% |
| 2005 Q3 | -3.44 Million USD | -12.66% |
| 2005 Q4 | -3.37 Million USD | 1.92% |
| 2005 FY | -11.9 Million USD | -18.8% |
| 2005 Q2 | -3.05 Million USD | -50.79% |
| 2004 Q1 | -2.06 Million USD | -21.87% |
| 2004 FY | -10.02 Million USD | -19.79% |
| 2004 Q4 | -2.24 Million USD | 22.71% |
| 2004 Q3 | -2.91 Million USD | -3.82% |
| 2004 Q2 | -2.8 Million USD | -35.94% |
| 2003 Q1 | -1.47 Million USD | 39.47% |
| 2003 Q3 | -3.35 Million USD | -81.4% |
| 2003 Q2 | -1.84 Million USD | -25.27% |
| 2003 FY | -8.36 Million USD | 24.02% |
| 2003 Q4 | -1.69 Million USD | 49.55% |
| 2002 Q3 | -1.66 Million USD | 39.27% |
| 2002 Q1 | -4.17 Million USD | -210.25% |
| 2002 FY | -11.01 Million USD | -166.11% |
| 2002 Q4 | -2.43 Million USD | -46.53% |
| 2002 Q2 | -2.74 Million USD | 34.31% |
| 2001 Q4 | 3.78 Million USD | 285.46% |
| 2001 Q1 | -2.14 Million USD | -2.86% |
| 2001 Q3 | -2.04 Million USD | 45.44% |
| 2001 Q2 | -3.73 Million USD | -74.48% |
| 2001 FY | -4.13 Million USD | 54.46% |
| 2000 Q4 | -2.08 Million USD | 22.52% |
| 2000 Q2 | -1.49 Million USD | 46.99% |
| 2000 FY | -9.08 Million USD | 13.03% |
| 2000 Q1 | -2.82 Million USD | 4.37% |
| 2000 Q3 | -2.68 Million USD | -79.87% |
| 1999 Q3 | -3.2 Million USD | -33.33% |
| 1999 Q2 | -2.4 Million USD | -41.18% |
| 1999 Q1 | -1.7 Million USD | 50.0% |
| 1999 FY | -10.44 Million USD | 9.14% |
| 1999 Q4 | -2.94 Million USD | 7.85% |
| 1998 Q3 | -3.4 Million USD | -21.43% |
| 1998 Q4 | -3.4 Million USD | 0.0% |
| 1998 Q1 | -1.9 Million USD | 20.83% |
| 1998 Q2 | -2.8 Million USD | -47.37% |
| 1998 FY | -11.5 Million USD | -41.98% |
| 1997 Q2 | -2.4 Million USD | -41.18% |
| 1997 FY | -8.1 Million USD | -35.0% |
| 1997 Q4 | -2.4 Million USD | -50.0% |
| 1997 Q3 | -1.6 Million USD | 33.33% |
| 1997 Q1 | -1.7 Million USD | -21.43% |
| 1996 Q1 | -1.5 Million USD | -66.67% |
| 1996 Q2 | -1.9 Million USD | -26.67% |
| 1996 Q3 | -1.2 Million USD | 36.84% |
| 1996 Q4 | -1.4 Million USD | -16.67% |
| 1996 FY | -6 Million USD | -62.16% |
| 1995 Q2 | -800 Thousand USD | 20.0% |
| 1995 Q4 | -900 Thousand USD | 10.0% |
| 1995 Q3 | -1 Million USD | -25.0% |
| 1995 FY | -3.7 Million USD | -32.14% |
| 1995 Q1 | -1 Million USD | -25.0% |
| 1994 Q3 | -900 Thousand USD | -80.0% |
| 1994 Q2 | -500 Thousand USD | 16.67% |
| 1994 Q1 | -600 Thousand USD | -20.0% |
| 1994 FY | -2.8 Million USD | -40.0% |
| 1994 Q4 | -800 Thousand USD | 11.11% |
| 1993 Q1 | -600 Thousand USD | -50.0% |
| 1993 Q3 | -300 Thousand USD | 50.0% |
| 1993 Q4 | -500 Thousand USD | -66.67% |
| 1993 FY | -2 Million USD | -25.0% |
| 1993 Q2 | -600 Thousand USD | 0.0% |
| 1992 Q2 | -400 Thousand USD | 0.0% |
| 1992 Q3 | -400 Thousand USD | 0.0% |
| 1992 Q4 | -400 Thousand USD | 0.0% |
| 1992 Q1 | -400 Thousand USD | 0.0% |
| 1992 FY | -1.6 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -491.801% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -13.179% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 114.917% |
| Nascent Biotech, Inc. | -2.08 Million USD | -278.558% |
| Rebus Holdings, Inc. | -1.02 Million USD | -674.813% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 112.134% |
| Qrons Inc. | -789.34 Thousand USD | -901.219% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1149.685% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 87.375% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1802.164% |
| Skye Bioscience, Inc. | -37.64 Million USD | 79.006% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 89.457% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -20.179% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2790.649% |
| SQZ Biotechnologies Company | -79.46 Million USD | 90.054% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -173.237% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -334.11% |
| Mesoblast Limited | -87.95 Million USD | 91.015% |
| Marizyme, Inc. | -65.34 Million USD | 87.906% |
| Genus plc | 7.9 Million USD | 200.039% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 27.44% |
| Pharming Group N.V. | -10.54 Million USD | 25.075% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -264.229% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -113.008% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 10.639% |
| ContraFect Corporation | -65.15 Million USD | 87.87% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -61.748% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -357.499% |
| IMV Inc. | -36.48 Million USD | 78.339% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 1.943% |
| MultiCell Technologies, Inc. | -380.07 USD | -2079278.272% |
| ONE Bio Corp. | 8.67 Million USD | 191.085% |
| Accustem Sciences Inc. | -3.74 Million USD | -110.951% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 84.711% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -523.698% |
| Q BioMed Inc. | -2.05 Million USD | -285.124% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -111.709% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -231.941% |
| Biomind Labs Inc. | -1.21 Million USD | -550.825% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 86.768% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -154.793% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -305.443% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -52671.721% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 50.206% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -35.856% |
| GB Sciences, Inc. | -1.36 Million USD | -480.394% |
| Alpha Cognition Inc. | -13.77 Million USD | 42.617% |
| HST Global, Inc. | -146.21 Thousand USD | -5305.303% |
| CSL Limited | 2.64 Billion USD | 100.299% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -350.377% |
| Halberd Corporation | -79.67 Thousand USD | -9819.038% |
| Enzolytics Inc. | -2.17 Million USD | -263.055% |
| Agentix Corp. | -1.37 Million USD | -475.1% |
| Resverlogix Corp. | -3.61 Million USD | -118.922% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -149.196% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.321% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 8164.381% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 214.131% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -98.92% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -161.161% |
| AVAX Technologies, Inc. | -6.41 Million USD | -23.223% |
| Zenith Capital Corp. | -10.59 Million USD | 25.414% |
| Genscript Biotech Corporation | -95.47 Million USD | 91.723% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -33903.498% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -90.623% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -12975.8% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -294.147% |
| Kadimastem Ltd | -3.3 Million USD | -138.952% |
| Helix BioMedix, Inc. | -1.05 Million USD | -648.359% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -106.941% |
| BioStem Technologies, Inc. | -8.48 Million USD | 6.836% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1690.586% |
| LadRx Corporation | 400.44 Thousand USD | 2073.588% |
| Cell Source, Inc. | -5.32 Million USD | -48.521% |
| Regen BioPharma, Inc. | 1.02 Million USD | 872.157% |
| Regen BioPharma, Inc. | 1.02 Million USD | 872.157% |
| NovAccess Global Inc. | -4.76 Million USD | -65.712% |
| Affymax, Inc. | -14.42 Million USD | 45.209% |
| Itoco Inc. | -1.86 Million USD | -322.853% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -77.896% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -373.523% |
| Mobile Lads Corp. | -2.26 Million USD | -249.186% |
| CytoDyn Inc. | -49.84 Million USD | 84.143% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -9899.738% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -3364.339% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -739.389% |
| SYBLEU INC | -180.3 Thousand USD | -4283.204% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -390.042% |
| International Stem Cell Corporation | -131 Thousand USD | -5932.895% |
| Bioxytran, Inc. | -4.28 Million USD | -84.652% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -14462.008% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -212.345% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 83.56% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -273.845% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -912.066% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -149.466% |
| Neutra Corp. | -233.46 Thousand USD | -3285.13% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 61.051% |
| PureTech Health plc | -65.69 Million USD | 87.97% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 62.838% |
| IXICO plc | -1.17 Million USD | -570.891% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 20.388% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 86.166% |
| CSL Limited | 2.64 Billion USD | 100.299% |
| Cellectis S.A. | -103.17 Million USD | 92.34% |